Verified Nov 2026
Batteries & E-Mobility
·
Seattle, Washington
·
Since 2009
Adaptive Biotechnologies Corp. is a biotechnology company headquartered in Seattle, Washington, founded in 2009 and listed on Nasdaq under the ticker ADPT. It employs between 500 and 1,000 people and reports revenue in the range of $277 million. The company develops immune-driven diagnostics and therapeutics for cancer, autoimmune conditions, and infectious diseases, serving the automotive, electric-vehicle, and medical sectors. Its clonoSEQ test detects and monitors minimal residual disease in hematologic malignancies. In June 2026, the company announced a plan to separate its MRD and immune medicine businesses.
Adaptive Biotechnologies Corp. at a glance
Revenue
277.0M
Employees
500-1,000
Founded
2009
Headquarters
Seattle, Washington
Ownership
Publicly traded (NASDAQ: ADPT)
Certifications
ISO 13485
Industries
Automotive
Electric Vehicles
Medical
STABILITY SIGNALS
Established & strong
17 years in operation (founded 2009).
Publicly listed; no distress event on record.
Holds ISO 13485 certification(s) per public sources.
Overview
Adaptive Biotechnologies Corp. is a biotechnology company headquartered in Seattle, Washington, founded in 2009 and listed on Nasdaq under the ticker ADPT. It employs between 500 and 1,000 people and reports revenue in the range of $277 million. The company develops immune-driven diagnostics and therapeutics for cancer, autoimmune conditions, and infectious diseases, serving the automotive, electric-vehicle, and medical sectors. Its clonoSEQ test detects and monitors minimal residual disease in hematologic malignancies. In June 2026, the company announced a plan to separate its MRD and immune medicine businesses.
At a glance
Attribute | Detail |
|---|---|
Founded | 2009 |
Headquarters | Seattle, Washington |
Employees | 500-1,000 |
Revenue | 277.0M |
Ownership | Publicly traded (NASDAQ: ADPT) |
Primary capability | Batteries & E-Mobility |
Certifications | ISO 13485 |
What Adaptive Biotechnologies Corp. makes
The company holds ISO 13485 certification and offers immune sequencing products, including the clonoSEQ and immunoSEQ platforms, along with the T-Detect cancer detection test.
Products and capabilities described on the company's own site include Glass (source: adaptivebiotech.com).
Certifications
Adaptive Biotechnologies Corp. is associated with the following certifications in public sources. Confirm the certified scope for the specific plant producing your part:
ISO 13485 — adaptivebiotech.com
Latest developments
2026-11-04 — Adaptive Biotechnologies Reports Third Quarter 2026 (globenewswire.com)
2026-06-17 — Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering | Adaptive Biotechnologies (adaptivebiotech.com)
2026-06-15 — Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses | Adaptive Biotechnologies (adaptivebiotech.com)
2026-06-15 — Adaptive Biotechnologies Corporation Announces Proposed (globenewswire.com)
2026-01-06 — Adaptive Biotechnologies spinout raising $15M to develop clinical sequencing tech – GeekWire (geekwire.com)
2025-12-15 — Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer | Adaptive Biotechnologies (adaptivebiotech.com)
Company details
The company has been publicly listed on Nasdaq and has operated since 2009, with an office in South San Francisco, California, in addition to its Seattle headquarters. Adaptive Biotechnologies Corp. was founded in 2009, has an estimated 500-1,000 employees, and is headquartered in Seattle, Washington. On the LightSource stability read it is rated "Established & strong": 17 years in operation (founded 2009). Publicly listed; no distress event on record. Holds ISO 13485 certification(s) per public sources.
Frequently asked questions
What does Adaptive Biotechnologies Corp. make?
Adaptive Biotechnologies Corp. is a biotechnology company headquartered in Seattle, Washington, founded in 2009 and listed on Nasdaq under the ticker ADPT. It employs between 500 and 1,000 people and reports revenue in the range of $277 million. The company develops immune-driven diagnostics and therapeutics for cancer, autoimmune conditions, and infectious diseases, serving the automotive, electric-vehicle, and medical sectors. Its clonoSEQ test detects and monitors minimal residual disease in hematologic malignancies. In June 2026, the company announced a plan to separate its MRD and immune medicine businesses.
Where is Adaptive Biotechnologies Corp. headquartered?
Adaptive Biotechnologies Corp. is headquartered in Seattle, Washington (1165 Eastlake Ave E, Seattle, Washington, 98109-4456).
When was Adaptive Biotechnologies Corp. founded?
Adaptive Biotechnologies Corp. was founded in 2009.
How big is Adaptive Biotechnologies Corp.?
Adaptive Biotechnologies Corp. has an estimated 500-1,000 employees, with revenue in the 277.0M range.
Is Adaptive Biotechnologies Corp. publicly traded?
Publicly traded (NASDAQ: ADPT). Public financial figures are drawn from its filings.
What certifications does Adaptive Biotechnologies Corp. hold?
Adaptive Biotechnologies Corp. lists ISO 13485 on its website. Confirm the certified scope for the specific plant producing your part.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.